Cardiol Therapeutics Sets June 24, 2026 Date for Annual General Meeting of Shareholders
Easter Sale - 70% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Cardiol Therapeutics ( (TSE:CRDL) ).
On April 10, 2026, Cardiol Therapeutics Inc. filed a Form 6-K with the U.S. Securities and Exchange Commission, confirming its status as a foreign private issuer reporting under Form 40-F and providing an exhibit related to shareholder governance matters. The filing was executed by Chief Financial Officer Christopher Waddick from the company’s Oakville, Ontario headquarters, underscoring Cardiol’s ongoing compliance with cross-border disclosure requirements.
In a notice filed the same day via Canadian regulators, the company announced it will hold its annual general meeting of securityholders on June 24, 2026, with a record date of May 7, 2026 for notice and voting eligibility. Only holders of Class A common shares as of that date will be entitled to vote, and Cardiol has opted to use notice-and-access delivery and to pay for proxy material distribution to objecting beneficial owners, signaling a standardized governance process for investors ahead of the meeting.
The meeting arrangements, administered by Odyssey Trust Company as Cardiol’s agent, detail that proxy materials will not be sent directly to non-objecting beneficial owners but will be made available under notice-and-access protocols. These steps clarify the mechanics for shareholder participation, which can be relevant for institutional and retail investors assessing their ability to exercise voting rights in the upcoming governance cycle.
The most recent analyst rating on (TSE:CRDL) stock is a Hold with a C$2.00 price target. To see the full list of analyst forecasts on Cardiol Therapeutics stock, see the TSE:CRDL Stock Forecast page.
Spark’s Take on CRDL Stock
According to Spark, TipRanks’ AI Analyst, CRDL is a Neutral.
The score is held back primarily by weak financial performance (pre-revenue, sizable losses, and sustained cash burn), partially offset by a low-debt balance sheet. Technicals are a positive contributor with an improving uptrend and constructive momentum, while valuation remains constrained due to negative earnings and no dividend support.
To see Spark’s full report on CRDL stock, click here.
More about Cardiol Therapeutics
Cardiol Therapeutics Inc. is a foreign private issuer listed in the United States that files its continuous disclosure reports under Form 40-F. The Canada-based company is incorporated as Cardiol Therapeutics Inc. and maintains its principal executive offices in Oakville, Ontario, reflecting its operational base in the Canadian life sciences and capital markets environment.
As a cross-border issuer, Cardiol Therapeutics is subject to both Canadian securities regulation and U.S. reporting requirements. Its Class A common shares are identified under ISIN CA14161Y2006, and it uses Odyssey Trust Company as an agent for shareholder communications and meeting administration across applicable exchanges and securities regulators.
Average Trading Volume: 121,397
Technical Sentiment Signal: Buy
Current Market Cap: C$210.3M
For detailed information about CRDL stock, go to TipRanks’ Stock Analysis page.
